Type 1 diabetes: New perspectives on disease pathogenesis and treatment

Lancet

Volumn 358, Issue 9277, 2001, Pages 221-229

  Atkinson, Mark A ^a   Eisenbarth, George S ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

BLOOD GLUCOSE MONITORING; CONFERENCE PAPER; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; GENETIC ANALYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

EID: 0035928391     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)05415-0     Document Type: Conference Paper

References (95)

1. Type 1 diabetes: A chronic autoimmune disease of human, mouse, and the rat
2. The pathogenesis of insulin dependent diabetes
3. Autoimmune diabetes in NOD mice: A genetic program interruptible by environmental manipulation
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
5. Geographic differences in the risk of insulin-dependent diabetes mellitus: The importance of registries
6. Variation and trends in incidence of childhood diabetes in Europe
7. Worldwide increase in incidence of Type 1 diabetes - The analysis of the data on published incidence trends
8. Incidence of childhood-onset insulin-dependent diabetes mellitus: The EURODIAB ACE study
9. New insights into the epidemiology of type 1 diabetes in Mediterranean countries
10. From genome to aetiology in a multifactorial disease, type 1 diabetes
11. Dissecting the genetics of type 1 diabetes: Relevance for familial clustering and differences in incidence
12. Sometimes it is hot, sometimes it's not
13. Human type 1 diabetes and the insulin gene: Principles for mapping polygenes
14. The CTLA-4 gene region on chromosome 2q33 is linked to and associated with type 1 diabetes
15. Early infant diets and insulin-dependent diabetes
16. Viruses and other perinatal exposures as initiating events for beta-cell destruction
17. Environmental factors in the pathogenesis of type 1 diabetes mellitus
18. Lack of association between early exposure to cow's milk protein and beta-cell autoimmunity. Diabetes Autoimmunity Study in the Young
19. Lack of association between early childhood immunizations and beta-cell autoimmunity
20. No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB Study
21. Infant feeding, early weight gain, and risk of type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group
22. Enterovirus RNA in serum is a risk factor for beta-cell autoimmunity and clinical type 1 diabetes: A prospective study
23. Cow's milk consumption, HLA-DQB1 genotype, and type 1 diabetes: A nested case-control study of siblings of children with diabetes
24. Genes versus environment in insulin-dependent diabetes: The phoney war
25. Non-specific viral infections as possible synchronising events of the manifestation of type 1 diabetes
26. Type 1 diabetes mellitus. A chronic autoimmune disease
27. Perinatal and neonatal determinants of childhood type 1 diabetes: A case-control study in Yorkshire, U.K.
28. Infections and vaccinations as risk factors for childhood type 1 (insulin-dependent) diabetes mellitus: A multicentre case-control investigation. EURODIAB Substudy 2 Study Group
29. Infections and risk of Type I (insulin-dependent) diabetes mellitus in Lithuanian children
30. Acceleration of type 1 diabetes by a coxsackievirus infection requires a preexisting critical mass of autoreactive T-cells in pancreatic islets
31. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: The 2-year analysis of the German BABYDIAB study
32. Disease-associated autoantibodies as surrogate markers of type 1 diabetes in young children at increased genetic risk. Childhood Diabetes in Finland Study Group
33. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: Evidence for early determination of subsequent diabetes
34. Islet autoimmunity in infants with a Type 1 diabetic relative is common but is frequently restricted to one autoantibody
35. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus
36. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency
37. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group
38. A novel subtype of Type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies
39. The histopathology of the pancreas in Type 1 (insulin-dependent) diabetes mellitus: A 25-yr review of deaths in patients under 20 years of age in the United Kingdom
40. Immunological abnormalities in islets at diagnosis paralleled further deterioration of glycaemic control in patients with recent-onset Type 1 (insulin-dependent) diabetes mellitus
41. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset type 1 diabetes mellitus
42. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies
43. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop
44. The combination of antibodies to GAD-65 and IA-2ic can replace the islet-cell antibody assay to identify subjects at risk of type 1 diabetes mellitus
45. Disease-associated autoantibodies as surrogate markers of type 1 diabetes in young children at increased genetic risk. Childhood Diabetes in Finland Study Group
46. Islet cell autoantibodies reactive to glutamate decarboxylase in insulin dependent diabetes
47. The fourth international serum exchange workshop to standardize cytoplasmic islet cell antibodies. The immunology and diabetes workshops and participating laboratories
48. Prevention of type 1 diabetes
49. Now is the time to prevent type 1 diabetes
50. Safety of high-dose nicotinamide: A review ENDIT Group. European Nicotinamide Diabetes Intervention Trial
51. The Diabetes Prevention Trial-Type 1 diabetes (DPT-1): Implementation of screening and staging of relatives
52. Immunological heterogeneity in type 1 diabetes: Presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease
53. Genetic heterogeneity of autoimmune diabetes: Age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group
54. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
55. Immunological heterogeneity in type 1 diabetes: Presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease
56. Combined use of autoantibodies (IA-2ab, Gadab, IAA, ICA) in type 1 diabetes: Combinatorial islet autoantibody workshop
57. Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes
58. Thyroid autoimmunity in insulin-dependent diabetes mellitus: The case for routine screening
59. Association of insulin-dependent diabetes mellitus and celiac disease: A study based on serologic markers
60. Celiac disease in insulin-dependent diabetes mellitus
61. One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease associated transglutaminase autoantibodies
62. Silent celiac disease in children with a genetic risk
63. Addisonís disease: Serological studies
64. DRB1*04 and DQ alleles: Expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease
65. Autoimmune Polyendocrine Syndrome Type II
66. Geographic variation in mortality among individuals with youth-onset diabetes mellitus across the world
67. Mortality in patients with childhood-onset type 1 diabetes in Finland, Estonia, and Lithuania: Follow-up of nationwide cohorts
68. Risk factors fir cerebral edema in children with diabetic ketoacidosis
69. Cerebral edema and ophthalmoplegia reversed by mannitol in a new case of insulin-dependent diabetes mellitus
70. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
71. Epidemiology of severe hypoglycemia in the diabetes control and complications trial
72. Genetically engineered insulin analogs: Diabetes in the new millennium
73. Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus
74. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes
75. Effectiveness of postprandial Humalog in toddlers with diabetes
76. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump
77. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes
78. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
79. Insulin glargine
80. Subcutaneous glucose predicts plasma glucose independent of insulin: Implications for continuous monitoring
81. The MiniMed Continuous Glucose Monitoring System (CGMS)
82. Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes
83. Prevention of recurrent hypoglycemia in type 1 diabetes by pancreas transplantation
84. Islet transplantation in seven patients with type 1 diabetes mellitus using a flucocorticoid-free immunosuppressive regimen
85. Twin-to-twin pancreas transplantation: Reversal and re-enactment of the pathogenesis of type I diabetes
86. Metabolic characterization of long-term successful pancreas transplants in type I diabetes
87. Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure
88. Islet cell transplantation: The future?
89. Remission of type 1 diabetes by gene therapy using a single-chain insulin analogue
90. Glucose-dependent insulin release from genetically engineered K cells
91. The diabetic retinopathy study and the early treatment of diabetic retinopathy study
92. The role of digital fundus photography in diabetic retinopathy screening
93. Renoprotection in diabetes: Genetic and non-genetic risk factors and treatment
94. Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications?
95. Assessment and management of foot disease in patients with diabetes